<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We have identified a membrane-bound form of M-CSF (m-M-CSF) from an established human leukemic J6-1 cell line </plain></SENT>
<SENT sid="1" pm="."><plain>To further understand its biological significance, we studied the expression of this membrane-associated growth factor in the lymph nodes of <z:hpo ids='HP_0002665'>lymphoma</z:hpo> patients and bone marrow smears from patients with <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematologic diseases</z:e> by immunohistochemical staining using anti-M-CSF MAb </plain></SENT>
<SENT sid="2" pm="."><plain>We detected a high incidence of m-M-CSF expression in 75% (9/12) of the lymph node sections from patients with <z:e sem="disease" ids="C0019829" disease_type="Neoplastic Process" abbrv="hd">Hodgkin's Disease</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>The antigens were detected primarily in large clusters of mononuclear Hodgkin's cells and the extracellular matrix (EM) surrounding them </plain></SENT>
<SENT sid="4" pm="."><plain>In one <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> patient with abundant multinucleated Reed-Sternberg (R-S) cells, <z:hpo ids='HP_0000001'>all</z:hpo> of them were intensely stained with anti-M-CSF MAb </plain></SENT>
<SENT sid="5" pm="."><plain>In non-Hodgkin's <z:hpo ids='HP_0002665'>lymphomas</z:hpo> (NHL), the incidence (17.6 %) of m-M-CSF expression was lower (3/17) </plain></SENT>
<SENT sid="6" pm="."><plain>Yet, no m-M-CSF antigens were detected in the lymph nodes from six cases of <z:e sem="disease" ids="C0935681" disease_type="Neoplastic Process" abbrv="">non-hematologic malignancies</z:e> and other diseases </plain></SENT>
<SENT sid="7" pm="."><plain>A high response also was detected in bone marrow smears obtained from patients with <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e>, which include myeloid <z:hpo ids='HP_0001909'>leukemias</z:hpo> (32.5%), <z:hpo ids='HP_0002665'>lymphomas</z:hpo> with bone marrow <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> (50%) and <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) (37.5 %) </plain></SENT>
<SENT sid="8" pm="."><plain>By comparison, only 6.8 % of bone marrow smears from non-malignant <z:e sem="disease" ids="C0018939" disease_type="Disease or Syndrome" abbrv="">hematologic diseases</z:e> and 2.7% of <z:hpo ids='HP_0005526'>lymphoid leukemias</z:hpo> showed positive staining with anti-M-CSF MAb </plain></SENT>
<SENT sid="9" pm="."><plain>Our results showed that high expression of m-M-CSF antigens is linked to some types of <z:hpo ids='HP_0002665'>lymphomas</z:hpo>, especially <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>. and myeloid <z:hpo ids='HP_0001909'>leukemias</z:hpo>, and may play a role in the development of these <z:e sem="disease" ids="C0376545" disease_type="Neoplastic Process" abbrv="">hematologic malignancies</z:e> </plain></SENT>
</text></document>